Skip to content

Tango Therapeutics

US · TNGX #2322 by market cap Listed 1970
21.83 -0.07 -0.32%
Live - 5344 symbols - heartbeat 220s ago · 2026-10-08 08:28
Pre-market 21.71 -0.55%
After-hours 21.83 0.00%
Market cap
3.68B
P/B
3.59
EPS
-0.87
Reader sentiment Are you bullish or bearish on TNGX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $27 to $40
    Market Newswire · 2026/5/14
  • Rating change
    Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $35
    Market Newswire · 2026/8/12
  • Rating change
    Leerink Partners Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/5/15
  • Rating change
    Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/6/26
  • H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $68
    Market Newswire · 2026/8/18
  • Rating change
    A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66
    Market Newswire · 2026/6/10
  • Rating change
    A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $35 to $42
    Market Newswire · 2026/6/9
  • Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)
    TipRanks · 2026/8/12
  • Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/9/24
  • Rating change
    CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/6/11
  • CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46
    Market Newswire · 2026/9/24
  • Rating change
    Mizuho Securities Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/5/15
  • Rating change
    Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60
    Market Newswire · 2026/6/26
  • Rating change
    H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66
    Market Newswire · 2026/6/11
  • Rating change
    CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/5/22
  • Rating change
    A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $27 to $55
    Market Newswire · 2026/5/15
  • Rating change
    CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $46
    Market Newswire · 2026/6/29
  • Rating change
    Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/8/17
  • Wedbush Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $39
    Market Newswire · 2026/8/12
  • Rating change
    J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46
    Market Newswire · 2026/7/15

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:28:53 · For reference only, not investment advice and not tailored to your situation.